A Comparison of the Visual Performance of Trifocal Versus Extended Depth of Focus Intraocular Lenses
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03726606 |
|
Recruitment Status : Unknown
Verified October 2018 by Hashmanis Hospital.
Recruitment status was: Not yet recruiting
First Posted : October 31, 2018
Last Update Posted : October 31, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cataract Lenses Visual Impairment | Device: Intraocular lens | Not Applicable |
To compare the clinical performance, quality of vision and subjective outcomes between the extended depth of focus (EDOF) Mini Well Ready intraocular lens (IOL) and the diffractive trifocal PanOptix IOL, at 3 months following second eye implantation.
Statistical analysis
All data will be analyzed using the Statistical Package for the Social Sciences (SPSS) v23 (SPSS Inc., Chicago, IL, USA). Graphs will be made using SPSS and Microsoft Excel (Microsoft Corp., Redmond, WA, USA). Normality will be tested for using the Shapiro Wilk test. If the data is normal, an independent t test will be used for comparing the continuous variables between the groups. If the data is not normal, then we will utilize the Mann Whitney U test.
Sample size calculation
The sample size calculation was based on the mean binocular Uncorrected Near Visual Acuity (UNVA) tested at 40cm under photopic condition. A previous study on the same diffractive trifocal IOL revealed a binocular UNVA of 0.01 ± 0.087 logMAR (12). The anticipated mean value for Mini Well Toric Ready is 0.10 logMAR. Based on these assumptions, an alpha of 0.05 and power of 0.8, it was calculated a number of 15 patients implanted bilaterally for each group. Assuming a dropout rate of 20% on the primary outcome measure, this resulted in a total number of 36 bilateral patients, 18 each group.
Duration of the project: Six months to one year
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 36 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Participants will be randomly allocated to one of two arms: Trifocal or extended depth of focus intraocular lenses. |
| Masking: | Double (Participant, Outcomes Assessor) |
| Masking Description: | The patient and the examiner will be blinded to the arms. |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Controlled, Two-armed, and Single Blind Trial Evaluating the Visual Performance and Quality of Vision After Bilateral Implantation of 2 Presbyopia Correcting Intraocular Lenses: Trifocal Versus Extended Depth of Focus |
| Estimated Study Start Date : | November 5, 2018 |
| Estimated Primary Completion Date : | May 6, 2019 |
| Estimated Study Completion Date : | May 6, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Extended depth of focus intraocular lens
Bilateral implantation of extended depth of focus intraocular lenses.
|
Device: Intraocular lens
Bilateral implantation of the same intraocular lens.
Other Name: Phacoemulsifcation |
|
Active Comparator: Trifocal intraocular lens
Bilateral implantation of trifocal intraocular lenses.
|
Device: Intraocular lens
Bilateral implantation of the same intraocular lens.
Other Name: Phacoemulsifcation |
- Near Visual Acuity (Corrected and Uncorrected) [ Time Frame: 3 months after bilateral implantation ]40 cm
- Intermediate Visual Acuity (Corrected and Uncorrected) [ Time Frame: 3 months after bilateral implantation ]66 cm
- Distance Visual Acuity (Corrected and Uncorrected) [ Time Frame: 3 months after bilateral implantation ]4 m
- Defocus Curve [ Time Frame: 3 months after bilateral implantation ]Evaluating presbyopia correction
- Objective Automated Refraction [ Time Frame: 3 months after bilateral implantation ]Using a auto refractometer (Topcon KR-800, Tokyo, Japan)
- Contrast Sensitivity [ Time Frame: 3 months after bilateral implantation ]At 2.5 m
- Higher Order Abberations [ Time Frame: 3 months after bilateral implantation ]Using a Abberometer
- Halos and Glares [ Time Frame: 3 months after bilateral implantation ]Using custom software provided by SIFI
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient aged 30 years of age or older
- Has bilateral cataracts with visual problems
- Is motivated for vision correction
Exclusion Criteria:
-
Any ocular pathology that could impair vision, for example:
- Pseudoexfoliation syndrome
- Zonular weakness
- Retinal or corneal dystrophies
- Retinal pathologies like age related macular degeneration
- History of trauma
- History of ocular surgery
- Individuals having trouble understanding written or spoken language
- Those with dense cataracts causing problems with optical biometry
- Average corneal powers outside the range of 41 diopters (D) to 46 D
- Corneal astigmatism > 0.75 D
- Irregular astigmatism index of 0.54 or higher
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03726606
| Contact: Nauman Hashmani, MBBS | 00923212828062 | naumanhashmani@hashmanis.edu.pk | |
| Contact: Sharif Hashmani, FCPS | 00923008255771 | yashhashmani@hotmail.com |
| Principal Investigator: | Sharif Hashmani, FCPS | Hashmanis Hospital |
| Responsible Party: | Hashmanis Hospital |
| ClinicalTrials.gov Identifier: | NCT03726606 |
| Other Study ID Numbers: |
HASH00011 |
| First Posted: | October 31, 2018 Key Record Dates |
| Last Update Posted: | October 31, 2018 |
| Last Verified: | October 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Cataract Intraocular lenses Trifocal intraocular lenses Extended depth of focus intraocular lenses Presbyopia |
|
Vision Disorders Vision, Low Cataract Lens Diseases |
Eye Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases |

